A Randomised, Double-blind, Placebo Controlled Study to Determine the Safety, Pharmacokinetics and Efficacy of Topical ZPL-5212372 Ointment Administered BID for up to 2 Weeks in Healthy Subjects and Subjects With Atopic Dermatitis.
Phase of Trial: Phase I/II
Latest Information Update: 21 Jul 2017
At a glance
- Drugs ZPL 5212372 (Primary)
- Indications Atopic dermatitis
- Focus Adverse reactions; Proof of concept
- Sponsors Ziarco
- 20 Mar 2017 Status changed from recruiting to completed.
- 09 Jun 2016 Status changed from planning to recruiting.
- 03 Feb 2016 New trial record